<DOC>
	<DOCNO>NCT00377650</DOCNO>
	<brief_summary>Aim Primary percutaneous coronary intervention efficacy improvement DIVER CE thrombectomy system lead thrombus reduction . Study design : Multicenter , prospective , open , randomize . Primary endpoint : ST resolution &gt; 70 % 60 minute PCI Secondary endpoint : Thrombectomy system efficacy/passing trough lesion thrombus reduction accord TIMI thrombus scale ≥ 1 TIMI 3 flow PCI MBG 3 CMR – infarct size , measurement leave ventricular end-diastolic EDV end-systolic volume ESV ejection fraction ( EF ) ECHO : measurement leave ventricular end-diastolic EDV end-systolic volume ESV , ejection fraction ( EF ) wall motion score index ( WMSI ) Major cardiac event /cardiac death , reMI , rePCI ( TVR , TLR , non infarct involve vessel ) CABG/ 6 month follow Rate composite angiographic adverse event include : distal embolisation , transient no-reflow slow flow , final TIMI &lt; 3 , need bail GpIIb/IIIa inhibitor adenosine nitroprosside , final thrombus score &gt; 1</brief_summary>
	<brief_title>Polish-Italian-Hungarian RAndomized ThrombEctomy Trial</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>ST elevation acute myocardial infarction within 6 hour since pain onset , 2 mm ST segment elevation two lead Minimum 3 mm ST segment elevation one lead Vessel reference diameter &gt; 2.5 mm When vessel reference diameter ≥ 4,0 mm additional distal protection device ( filter ) need stent implantation Contraindications PCI ( contrast allergy , possibility stent implantation ) ASA , thienopirydins GP IIb/IIIa inhibitor Active bleeding coagutopathy Prior CABG PCI Known ejection fraction EF &lt; 35 % Cardiogenic shock /SBP &lt; 90 mmHg , IABP and/or catheloamins usage/ LBBB , pacemaker rhythm Severe calcification Previous Myocardial infarction Stroke history Patient directly reanimation Known thrombocytopenia platelets &lt; 100 000 Pregnancy Cancer disease No future patient cooperation expect Patient ’ take part clinical trial Fibrynolisis directly administer PCI Renal insufficiency ( creatynine &gt; 220 µmol/ml ) , hemodialysis Contraindications PCI ( contrast allergy , possibility stent implantation ) ASA , thienopirydins GP IIb/IIIa inhibitor Active bleeding coagutopathy Prior CABG PCI Known ejection fraction EF &lt; 35 % Cardiogenic shock /SBP &lt; 90 mmHg , IABP and/or catheloamins usage/ LBBB , pacemaker rhythm Severe calcification Previous Myocardial infarction Stroke history Patient directly reanimation Known thrombocytopenia platelets &lt; 100 000 Pregnancy Cancer disease No future patient cooperation expect Patient ’ take part clinical trial Fibrynolisis directly administer PCI Renal insufficiency ( creatynine &gt; 220 µmol/ml ) , hemodialysis Liver insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>